New hope for aggressive brain cancer: combo therapy enters phase 2 trial
NCT ID NCT07326566
First seen Jan 09, 2026 · Last updated May 09, 2026 · Updated 20 times
Summary
This study tests whether adding silevertinib (an oral targeted therapy) to standard chemotherapy (temozolomide) helps people with a specific type of newly diagnosed glioblastoma live longer without their cancer growing. About 162 adults whose tumors have certain genetic markers (EGFRvIII and unmethylated MGMT) will be randomly assigned to get the combo or temozolomide alone after surgery and radiation. The goal is to see if the combination improves progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health
RECRUITINGSummit, New Jersey, 07901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Highlands Oncology Group
RECRUITINGSpringdale, Arkansas, 72762, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.